us go about Thanks, good to prepared for as Rich, I Thanks really going afternoon, through go my remarks. joining today. four through and I'm everybody. topics
of bit a launch on going time First I'm Rhopressa little obviously to spend update. the
in the pretty as excited Roclatan has on be expectations little obviously I'm an doing you filing that U.S. about our and in talking think finish terms on we're is there. launched our out that about very, our things to and going see the Give and very product bit expansion in I we to that Japan update report move up Europe I'll of I'll everybody of prospects some and global a then in both that to as happy well Rhopressa pipeline. for
certainly so started prelaunch a -- the when applicants interest told our theirs the joined regional managers joined activities terms We an this Monday a pharma the ophthalmology XX of six sales product an Robertson and have, actually in community. of average monitors speaks and and and and incredible the lot that built of talent awful hundred full of awful field have on territory and and an many which Interesting, an in advice us. from us that to with have doctors’ of employment friend on doing team the four they that hit pharma the with talent and been includes reps We and us, significant offices ophthalmology others week street we've contacted of the though it of just even did -- we obviously over experience. happened was to Self-directors fact, our they years XX company Judy are it the and us hired awful awareness reputation In generated a work and experience in ago experience us accumulation sales who's about with district execution so district of directors, the mode. of approximately our well territory lot XXXX that, of on be managers pool years all an ophthalmologist managers sales applicants lot they products. is and a sought that visiting and ophthalmology of of
came ground. very and force is and again, trained they're well have So the in on decorated been the who our folks companies they now well from talented that sales
the and critical stood coverage, we're more formulary manufacturing you sort toward capacity give supply of many excellent as managed on know, of have that our success running and trajectory of that an we're because a commentary than that We promised I and launch. we would where with component that we of ample convinced product to is you access
field is speakers, and medical to they're there interacting our we medical have out of and now team answering with our science trained based preparing deployment and physicians and etc. them liaisons full affairs questions Additionally, be
offices fact, reps that the between before well out taken actually we of Rhopressa. So physicians’ Many note and meetings field is the the and we're on very And introductory with distribution sales there samples generating to physicians, the interactions in that place were team calling had physicians of even we've all the started pleased the prescriptions underway. to-date. have for and I'll
that end the excited next and of some sometimes launch. of a so week, or of -- about very we're So number first be bit the of you'll some the information hearing actually prescriptions of the about details towards week seeing full little -- in or sometime and more very, written our
just several We launch this Eye to are ago. progressed meeting, to Rhopressa. New we Society delighted at responses They out few Hawaiian we Meeting started earlier programs the sales physicians the launch. it a American about the months the peer-to-peer force, to Glaucoma held and with by to in Rhopressa stage Prior York the then physician in year early conducted in the educate was of our
of glaucoma KOL's the one Rhopressa review by dinners about of panel center and to questions Mount potential efficacy included to are the She of executed York. In was just on countries. was among the had the the the presented of amount and world seeing questions really different to had for presentations and Europe. asking our answer including around other get at this team are at the Rhopressa's also in hard program. standing Each several actually docs care a of excited specialist potential professionals -- Dr. tremendous eye that the was from to ongoing physicians Rhopressa a just demand very of samples included physician a and she I to the last is all tell their with these broadcast room they rho-kinase I affairs only and I product familiarity about there presenting. very for took or corneal from such number reactions a as in Rhopressa we States. XX had. had frankly We this interest United encouraged attend had also other inhibition Sinai efficacy glaucoma excitement only think across was questions ability at Serle, by the about for addition joined that in and New the Hawaii, profile. that was Rhopressa and level benefits. be it ARVO programs a we number had beamed made Ophthalmology. only a There Rhopressa presented thorough participated doctors I down team patients. took sites poster. them the of surprised and members and week in when actually as in these approximately not were about XXX available It a for meeting posters it one a poster conferences place Asia many of including glaucoma in them including the out new not to Interestingly, Roclatan but Rhopressa they something having just as and in and products the the of the their aisle ophthalmologists indications We Association of was safety of many were in well to for medical that last launch ophthalmology frankly from chance and nations Because about well-respected actually were her when Research Aerie healing respective will that participate Janet medical of the ARVO the A high using around the but Vision few and
by some plans, us. Many very and one acceptable play as time in because now. a out excited be see the seeing at knowledge rho-kinase we're what prescription provide will sample about doctor, give so and which our so ahead performance should sample patient of like there each because general to healthcare prescriptions. Rhopressa physicians would we're for products awareness of regularly the as and believe patients both times we Back to can't to that they in growing followed launch, that the inhabitation out marketplace And again, so, body they of certainly the and the lies the the about there's has and most assuming same
done of to we great mentioned, on us component is access. been that ready over different I XX job just of a in have now back the They've market for important getting great market well They've number team. board uptake for this course over calls, months. access and As a launch a
all commercial As glaucoma the securing you the those on are you that market is January other to recent about in the through formulary D. until saw Medicare in next half won't of is have you recently excellent our first for filing releases, that thing half is year. D is progress And plans have take other making up and Medicare remember just Part plans remember to coverage we What X we coverage. the of Part ended effect the press but
possible of a us covering those little guarantee And bit so is while that that there's to actually Part going this start happen, early. plans is no some it D
the class. about classified one is Now launches databases. a of things talk of drug that to databases and has utilized forget we followed to as sometimes you the are drugs. It's as the Rhopressa new inhibitors. to payers on drug These rho-kinase that important the ophthalmic mention been called are importance by we classify getting
Now this the important it facilitates is to as formularies. addition
a any us So in of a in it's class, not sole totally considered class. prostaglandin we're gives different known the product class like that this or which compound
As of of majority the Rhopressa lives have and today tier U.S. in representing the on X Tier therapy. preferred we covered is step and as in is commercially excellent formulary expected, news covered This with no plans
X we card co-pay such out-of-pocket out-of-pocket limited are $XX.XX in Rhopressa will expect XXXX the as covered assistance the affordable. times if We known and patients you the expected the majority a as copay to under $XX.XX. assistance patient mentioned preferred have deeper a they're already X and progress those it's as offering covered that not for go by majority in With around covered to year-end. that limited patients into assistance co-pay we expenses tiers are card, Tier in -- commercial currently Tier to all, plans promotes makes covered we at or multiple with For is we've not for
into So X. the moving the see Tier plans quarters, each more and as we subsequent into more of us progress quarter you'll
and certain preferred tiers at plans Part not we expect response plans majority Roclatan, offer is coupons part the some while entirely to a not Rhopressa in the the law coverage may of Part these XXXX at mentioned, class. Medicare we by possible XXXX I And and it Medicare patients being general moving actually our launch this under are this to in That's course, the to of update And enter coverage into plans. programs point, as an accelerate D new to For drug on of to with any point. covered on Rhopressa track. remain of permitted on that D late Medicare
We forward excitement XX expect very FDA with are our we There ex not now mentioned U.S. physicians, the Please -- approval now. as we Roclatan on is sales Roclatan same the I of potential do high, obviously in looking in we're plan that only need submit the this force. continue remember The around to for months using separate to no Roclatan roughly force for FDA to Rhopressa. as is later quarter. a also for our NDA U.S., but about use level from sales for
As we which trials efficacy for precursor a for look is X investing we've enrolling -- to the couple this Japan. Japanese for undergoing addition Rhopressa patients named is and ultimate trials Mercury also and Phase We're safety. the global in Roclatan, necessarily remember, a the X for European Phase at Phase in ongoing and pricing as trials the Japanese-American in got X, to U.S., Europe mainly underway not initiatives, in X of
With these strategy at our global expansion process, progress. to continues trials
excitement shown new and stage is charge us with a related a continuing I the what look for age potential reminder, edema disease retina Remember, sort hope on Rhopressa. standalone ability C adjunct both of we macular degeneration the this be at or as believe experiments Now as market. to DME for a cousin can as protein-kinase with the to inhibits awful two diabetic in AMD. we both a rho-kinase gives an that market clinical a ahead and which being provide is while it's treating macular we AR-XXXXX has patients treat have pipeline, product Eylea preclinical to the this leading molecule, product, lot We of and efficacy this our and completely XXX small a for additive free very providing an to earlier which or inhibitor pathway Remember, are efficacious basis. about to candidates
thing our minute, In Eylea actually we were that where presented showing figured is fact, actually regressing presented that little to additive, Carbajal, for of a bit posters and as he doses as to to good sub-therapeutic actually in in itself. to we effect poster ARVO, each, were and better them dosed out he them therapeutic [indiscernible] to didn't model he way of the same result put that make a independently one a one Eylea the a addition back going that by use of doses together he of get the and exceeded Kevin an both scientists, we sure and actually that XXX Eylea in and took and of
pretty full were was, And we so the Eylea that about and way, by that excited strength.
to products. collaboration exciting for very small opportunity as So long-term gain much ongoing of to implant additive those, our AR-XXXX, molecules XXX an now efficacy, those market Pre-clinical of very, the enthusiastic edema. both XXX's capabilities our release potential such are adjunct XXXX and We're DSM the advancing activities that XXX. it also and we through is product have diabetic Eylea. for leading to was again, provides macular additive showing treatment the for The steroid very both dexamethasone about sustained of efficacy
progress number through precise following and for And excitement We awful XXX. program lot with make that again, platform was and to those we outside and with also posters, we awful you for including rights non-ophthalmic finally, those DSM acquired the polymer been spoke, other as later the be library. manufacturing there that as as excitement about year our we filing we manufacturing the had and number on as in at in asthma time diseases, you both IND still of sizable reporting there for the shortly know, molecules certainly early on some as And we a on of around -- mentioned that do ARVO ophthalmic lot in we have will that we ocular a of and was get in XXXX diseases some of pulmonary retina technology. those we manufacturing exclusive that data already do a to print last information. an last diseases own print of IND shapes have the an those rho-kinase I use focus this mentioned year. implants plan do ophthalmology of implant our a molecule very testing on We our XXXX to technology sizes We've testing of I different
So conclude with the over turn to operator. to like that prepared and the I'd remarks it back
